Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. What is the efficacy of Taltz® (ixekizumab) in pediatric patients with moderate-to-severe plaque psoriasis?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the efficacy of Taltz® (ixekizumab) in pediatric patients with moderate-to-severe plaque psoriasis?

Significantly more pediatric patients treated with ixekizumab vs placebo achieved PASI 75 and sPGA (0,1) as early as week 4 and the responses were sustained or further improved through week 108 in the IXORA-PEDS clinical trial.

US_cFAQ_IXE201_GENERAL_EFFICACY_PEDS
US_cFAQ_IXE201_GENERAL_EFFICACY_PEDS
en-US

IXORA-PEDS: Clinical Trial in Pediatric Patients

Study Design

IXORA-PEDS was a multicenter, randomized, double-blind, placebo-controlled phase 3 study designed to evaluate the efficacy and safety of ixekizumab in pediatric patients aged 6 to <18 years with moderate-to-severe plaque psoriasis.1,2

Patients were randomized in a 2:1 ratio to receive ixekizumab every 4 weeks (Q4W) (N=115) or placebo (N=56). Patients who were randomized to ixekizumab were dosed based on body weight categories as shown in IXORA-PEDS: Ixekizumab Dosing Regimen Based on Patients' Body Weight. In select countries outside the United States, where etanercept is approved for severe pediatric psoriasis, 30 patients were randomized to open-label etanercept and dosed according to the etanercept label.1

IXORA-PEDS: Ixekizumab Dosing Regimen Based on Patients' Body Weight1

Patients' Body Weight

Starting Dose (Week 0)

Dose Q4W Thereafter

<25 kg

40 mg

20 mg

25 to 50 kg

80 mg

40 mg

>50 kg

160 mg (two 80 mg injections)

80 mg

Abbreviation: Q4W = every 4 weeks.

Following the double-blind treatment period, patients entered an open-label maintenance period where all patients, regardless of initial treatment, received ixekizumab Q4W (dose based on patients' body weight) through week 60.1 Following the maintenance period, patients continued on open-label ixekizumab Q4W through week 108 in the extension period.2

Efficacy Endpoints

The coprimary efficacy endpoints were the proportion of patients achieving 75% improvement from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA) score of 0 or 1 [sPGA (0,1)] at week 12. The gated secondary endpoints were

  • 90% improvement from baseline in Psoriasis Area and Severity Index (PASI 90) at week 12
  • sPGA (0) at week 12
  • 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100) at week 12
  • itch numeric rating scale (NRS) ≥4-point improvement at week 12
  • PASI 75 at week 4, and
  • sPGA (0,1) at week 4.1

IXORA-PEDS: Week 12 Efficacy

The coprimary and all gated secondary endpoints were achieved in IXORA-PEDS. As shown in IXORA-PEDS: PASI 75 and sPGA (0,1) Responses Through Week 12, ITT Population, NRI, significantly (p<.001) more patients treated with ixekizumab than placebo-treated patients achieved PASI 75 and sPGA (0,1) at week 4 and all assessment time points through week 12 (primary endpoint).1

Ixekizumab was also superior to placebo (p<.001) in PASI 90, PASI 100, and sPGA (0) at week 4 and all assessments through week 12 (see IXORA-PEDS: PASI 90, PASI 100, and sPGA (0) Responses Through Week 12, ITT Population, NRI).1

Moreover, ixekizumab was superior to placebo in ≥4-point improvement in itch at week 1 (p<.01) and Children's Dermatology Life Quality Index (CDLQI)/Dermatology Life Quality Index (DLQI) at week 4 (p<.001) and at all assessments for both patient-reported outcomes through week 12.3

IXORA-PEDS: PASI 75 and sPGA (0,1) Responses Through Week 12, ITT Population, NRI3

Figure 1 description: Significantly (p<.001) more patients treated with ixekizumab than placebo-treated patients achieved PASI 75 and sPGA (0,1) at week 4 and all assessment time points through week 12.

Abbreviations: ITT = intent-to-treat; IXE = ixekizumab; NRI = nonresponder imputation; PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; Q4W = every 4 weeks; sPGA = static Physician Global Assessment.
‡ p<.001 vs placebo (Fisher’s exact test).

IXORA-PEDS: PASI 90, PASI 100, and sPGA (0) Responses Through Week 12, ITT Population, NRI3

Figure 2 description: Significantly (p<.001) more patients treated with ixekizumab than placebo-treated patients achieved PASI 90, PASI 100, and sPGA (0) at week 4 and all assessment time points through week 12. 

Abbreviations: ITT = intent-to-treat; IXE = ixekizumab; NRI = nonresponder imputation; PASI 90 = 90% improvement from baseline in Psoriasis Area and Severity Index; PASI 100 = 100% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; Q4W = every 4 weeks; sPGA = static Physician Global Assessment.
‡ p<.001 vs placebo (Fisher’s exact test).

IXORA-PEDS: Week 48 Efficacy

Week 12 responses were sustained or further improved through week 48 (IXORA-PEDS: PASI 75 (Top Graph) and sPGA (0,1) (Bottom Graph) Response Rates Through Week 48, ITT Population, NRI and IXORA-PEDS: Efficacy Responses at Week 12 and Week 48).1

IXORA-PEDS: PASI 75 (Top Graph) and sPGA (0,1) (Bottom Graph) Response Rates Through Week 48, ITT Population, NRI1

Abbreviations: ITT = intent-to-treat; IXE = ixekizumab; NRI = nonresponder imputation; PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; Q4W = every 4 weeks; sPGA = static Physician Global Assessment.

* p<.05 vs placebo.
‡ p<.001 vs placebo.

IXORA-PEDS: Efficacy Responses at Week 12 and Week 481

 

Week 12

Placebo
N=56
n (%)

Week 12

Ixekizumab Q4W
N=115
n (%)

Week 48

Ixekizumab Q4W
N=115
n (%)

PASI 50

21 (38)

106 (92)a

106 (92)

PASI 75

14 (25)

102 (89)a

103 (90)

PASI 90

3 (5)

90 (78)a

95 (83)

PASI 100

1 (2)

57 (50)a

63 (55)

sPGA (0,1)

6 (11)

93 (81)a

93 (81)

sPGA (0)

1 (2)

60 (52)a

65 (57)

Itch NRS ≥4-point improvementb

8 (20)

59 (71)a

65 (78)

CDLQI/DLQI (0,1)c

13 (23)

74 (64)a

87 (76)

PatGA (0,1)

9 (16)

91 (79)a

99 (86)

Abbreviations: CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; NRS = numeric rating scale; PASI = Psoriasis Area and Severity Index; PatGA = Patient’s Global Assessment of Disease Severity; Q4W = every 4 weeks; sPGA = static Physician’s Global Assessment.

ap<.001 vs placebo.

bAssessed for patients with baseline itch NRS ≥4. Placebo, N=40; ixekizumab Q4W, N=83.

cCDLQI was assessed for patients 6 to 16 years of age. DLQI was assessed for patients ≥17 years of age.

IXORA-PEDS: Week 108 Efficacy

In the IXORA-PEDS clinical trial, patients achieved primary and gated secondary endpoints by week 12 and sustained through week 60 and week 108 (IXORA-PEDS: Efficacy at Week 60 and Week 108).4

IXORA-PEDS: Efficacy at Week 60 and Week 1084

All ixekizumab populations at combined treatment perioda

Week 60
(N=94)b
n (%)

Week 108
(N=94)b
n (%)

PASI 50

90 (95.7)

89 (94.5)

PASI 75

85 (90.0)

86 (91.7)

PASI 90

76 (80.3)

74 (79.0)

PASI 100

50 (53.2)

52 (55.1)

sPGA (0,1)

75 (80)

74 (78.3)

sPGA (0)

51 (54.2)

49 (52.4)

Itch NRS ≥4-point improvement

58 (82.9)c

55 (78.5)c

CDLQI/DLQI (0,1)

63 (67.0)d

67 (60.6)e

PatGA (0,1)

79 (83.9)

79 (83.5)

Abbreviations: CDLQI = Children’s Dermatology Life Quality Index; DLQI = Dermatology Life Quality Index; NRS = numeric rating scale; PASI 50/75/90/100 = 50%/75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; PatGA = Patient’s Global Assessment of Disease Severity; sPGA = static Physician’s Global Assessment.

aAll patients who were randomized to ixekizumab at week 0 (visit 2) and who received ixekizumab throughout their study participation. Missing data were imputed using modified nonresponder imputation unless otherwise specified. For results imputed by modified nonresponders imputation, response rates were obtained through the average response rate of imputation data.

bUnless stated otherwise.

cN=70.

dN=80.

eN=75.

PASI 75, PASI 90, PASI 100, sPGA (0,1), and sPGA (0) responses were sustained or further improved through week 108 (IXORA-PEDS: PASI 75/90/100 Responses Achieved by Week 12 Were Sustained Through Week 108 With Ixekizumab, mNRI and IXORA-PEDS: sPGA (0,1) and sPGA (0) Week 12 Responses Were Sustained Through Week 108 With Ixekizumab).4

IXORA-PEDS: PASI 75/90/100 Responses Achieved by Week 12 Were Sustained Through Week 108 With Ixekizumab, mNRI4

Figure 4 description: In the IXORA-PEDS clinical trial, PASI 75/90/100 were sustained through week 108.

Abbreviations: IXE = ixekizumab; mNRI = modified nonresponder imputation; PASI 75/90/100 = 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; Q4W = every 4 weeks.

IXORA-PEDS: sPGA (0,1) and sPGA (0) Week 12 Responses Were Sustained Through Week 108 With Ixekizumab4

Figure 5 description: In the IXORA-PEDS clinical trial, sPGA (0,1) and sPGA (0) week 12 responses were sustained through week 108.

Abbreviations: IXE = ixekizumab; mNRI = modified nonresponder imputation; Q4W = every 4 weeks; sPGA = static Physician Global Assessment; W = week.

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Study Group. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231-241. https://doi.org/10.1111/bjd.19147

2Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Investigators. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. 2022;158(5):533-541. https://doi.org/10.1001/jamadermatol.2022.0655

3Paller AS, Seyger MMB, Magariños GA, et al. Efficacy and safety of ixekizumab in a phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate-to-severe plaque psoriasis. Abstract presented at: 28th Annual Meeting of the European Academy of Dermatology and Venereology (EADV Virtual); October 9-13, 2019; Madrid, Spain.

4Paller AS, Seyger MMB, Magariños GA, et al. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis (IXORA-PEDS). JAMA Dermatology. 2022;158(5):533-541. https://doi.org/10.1001/jamadermatol.2022.0655

Date of Last Review: August 22, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly